1.95
+0.04(+2.09%)
Currency In USD
| Previous Close | 1.91 |
| Open | 1.9 |
| Day High | 2.09 |
| Day Low | 1.87 |
| 52-Week High | 9.26 |
| 52-Week Low | 1.17 |
| Volume | 1.33M |
| Average Volume | 2.09M |
| Market Cap | 42.65M |
| PE | -0.21 |
| EPS | -9.29 |
| Moving Average 50 Days | 2.3 |
| Moving Average 200 Days | 2.36 |
| Change | 0.04 |
If you invested $1000 in BioXcel Therapeutics, Inc. (BTAI) since IPO date, it would be worth $11.05 as of November 25, 2025 at a share price of $1.95. Whereas If you bought $1000 worth of BioXcel Therapeutics, Inc. (BTAI) shares 5 years ago, it would be worth $2.73 as of November 25, 2025 at a share price of $1.95.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes
GlobeNewswire Inc.
Oct 14, 2025 11:00 AM GMT
Completes clinical trials required by FDA for sNDA submission planned for the first quarter of 2026NEW HAVEN, Conn., Oct. 14, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intel
BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation
GlobeNewswire Inc.
Oct 13, 2025 11:00 AM GMT
NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company pioneering the use of artificial intelligence to develop transformative medicines in neuroscience, announced today that CEO V
BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements
GlobeNewswire Inc.
Sep 18, 2025 11:00 AM GMT
NEW HAVEN, Conn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it has received